Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Longitudinal Study of Urea Cycle Disorders
NCT00237315 · View on ClinicalTrials.gov ↗
Study Summary
Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose of this study is to perform a long-term analysis of a large group of individuals with various UCDs. The study will focus on the natural history, disease progression, treatment, and outcome of individuals with UCD.
Conditions Studied
Study Locations (15)
California
- University of California, Los Angeles — Los Angeles
- Stanford University Medical Center — Stanford
Other
- University of Heidelberg — Heidelberg
- University Children's Hospital — Zurich
Colorado
- Children's Hospital Colorado — Aurora
District of Columbia
- Children's National Medical Center — Washington D.C.
Massachusetts
- Children's Hospital Boston (UCDC New England Center) — Boston
Minnesota
- University of Minnesota — Minneapolis
New York
- Icahn School of Medicine at Mount Sinai — New York
Ohio
- Case Western Medical College — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2006-02 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237315
The ClinicalTrials.gov registry entry for NCT00237315 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrea Gropman, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Urea Cycle Disorders appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00237315 reports 15 study locations spanning 13 distinct geographic areas — top geographies include California, Other, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00237315 about?
NCT00237315 is a clinical study titled "Longitudinal Study of Urea Cycle Disorders". Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy, and coma. The purpose of this study is to perform a long-term analysis of a large group of individuals with various UCDs. The study will fo...
What is the current status of trial NCT00237315?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2006-02. Estimated completion is 2026-07.
What conditions does trial NCT00237315 study?
This clinical trial studies the following conditions: Urea Cycle Disorders, Brain Diseases, Metabolic, Inborn, Amino Acid Metabolism, Inborn Errors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00237315?
This trial is sponsored by Andrea Gropman, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00237315 being conducted?
This trial has 15 study locations across California, Colorado, District of Columbia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.